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ABSTRACT
An optimistic attitude is hypothesized to be beneficial when facing a life-threatening medical condition.
However, the actual relationship of high expectations for treatment success and medical outcome is contro-
versial. Using a prospective cohort of 313 autologous and allogeneic hematopoietic stem cell transplant
patients enrolled July 1996 through November 1999, we tested whether patient-reported expectations before
transplantation were associated with survival and quality of life following the procedure. Before transplanta-
tion, patients with higher expectations that the transplant procedure would go well had better mental and
emotional functioning, but similar physical status and medical condition to patients with less optimistic
expectations. In the first 2 months after transplantation, optimistic expectations were associated with better
survival (92% v 84%; relative risk for mortality 0.45, 95% confidence interval 0.22-0.92; P.03) controlling for
other physical and mental characteristics. However, by 6 months posttransplantation, survival and quality of life
were indistinguishable between patients with initially higher and lower expectations. Our data suggest an
association between more optimistic expectations and early survival following hematopoietic stem cell trans-
plantation, but this association is not present by 6 months posttransplantation.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Studies measuring patient expectations show that
most patients are overly optimistic about the likeli-
hood of treatment success [1-4]. However, whether
these high expectations affect treatment choices and
treatment success is controversial. One well-known
study found no relationship between survival and psy-
chosocial status such as social ties, life satisfaction, and
adjustment to illness [5,6]. However, several observa-
tional studies investigating dispositional optimism, de-
nial, and hardy psychologic response to stress found
these cognitive response patterns to be associated with
better quality of life, fewer complications from treat-
ment, and improved survival [7-16].
A better understanding of the relationship, if any,
between expectations and subsequent health outcomes
would help clarify whether a strong belief that “things
will go well” is actually associated with better response
to treatment. Indeed, if more optimistic expectations
are found to contribute directly to the success of
treatment and are modiﬁable, efforts to foster and
maintain a positive mental attitude could improve
outcomes. However, if these beliefs do not lead to
meaningful improvement in survival or quality of life,
then this has important ramiﬁcations as well. For
example, physicians sometimes express a reluctance to
discuss certain issues with patients because they are
fearful that they will destroy the patient’s hope or will
to live [17-23]. Data showing that there is little inde-
pendent role for treatment expectations in long-term
outcomes might lessen barriers to open discussion
about the possibility of poor outcomes and allow bet-
ter communication with patients and families.
Hematopoietic stem cell transplantation (HSCT)
is a high-risk, elective, potentially curative procedure
offered to patients with hematologic malignancies.
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Because most patients are expected to become very ill
from the therapy, and have a prolonged recovery pe-
riod even if things go well, any beneﬁcial effects of
optimistic expectations might be enhanced and thus
more detectable. We used data collected as part of a
prospective, longitudinal study of quality of life and
decision making among stem cell transplant recipients
to search for evidence that optimistic pretransplanta-
tion expectations are associated with improved out-




Three hundred thirteen patients were enrolled
before undergoing stem cell transplantation between
August 1996 and November 1999 at the Brigham and
Women’s Hospital and Dana-Farber Cancer Institute
(Boston, MA). The Institutional Review Boards of the
Brigham and Women’s Hospital and Dana-Farber
Cancer Institute approved the protocol. Adult patients
able to read English were mailed questionnaires, con-
sent forms for the study, and self-addressed, stamped
envelopes between 1 week and 3 months before their
hospital admission. Some patients could not be
reached before their hospitalization for HSCT be-
cause of logistic reasons. Surviving patients were again
mailed questionnaires at 6 months following trans-
plantation. The results reported here describe data
collected before May 1, 2001.
Disease status at the time of study enrollment was
categorized into 3 groups. Good-risk patients were
those with acute leukemia in ﬁrst complete remission,
stable-phase chronic myelogenous leukemia, or aplas-
tic anemia. Intermediate-risk patients were in second
or greater complete remission or had myelodysplastic
syndrome that was either untreated or in remission.
Poor-risk patients had relapsed or refractory diseases.
Details of the transplantation regimens, purging pro-
tocols, and graft-versus-host disease (GVHD) pro-
phylaxis are published and include combinations of
cyclophosphamide, total body irradiation, busulfan,
BCNU, etoposide, and melphalan for conditioning,
monoclonal antibody purging for autologous proce-
dures, and T-cell depletion or combinations of meth-
otrexate, cyclosporine, tacrolimus, and corticosteroids
for GVHD prophylaxis [24-28]. No patients received
reduced-intensity conditioning regimens.
Questionnaire
Pretransplantation expectations for treatment suc-
cess were classiﬁed a priori according to the response
to 2 questions: “I am optimistic that my transplant will
go well” and “If anything can go wrong with my
transplant, it will.” Patients responded using a 5-point
Likert scale: strongly disagree, somewhat disagree,
neutral, somewhat agree, or strongly agree. Patients
who endorsed strong agreement with the ﬁrst state-
ment and strong disagreement with the second state-
ment were considered to have “high” or “more opti-
mistic” expectations compared with all other
combinations of responses. Attempts to classify expec-
tations into more than 2 categories resulted in groups
too small for analysis. Dispositional optimism (a stable
personality trait) was not assessed [7,12,29].
Before transplantation, information on sociode-
mographics and prognostic estimates for cure with
transplantation, nonrelapse mortality by 1 year post-
transplantation, and expectations for several measures
of recovery were collected from patients. The pre-
transplantation questionnaire also captured worry
about relapse, worry about the transplant, feelings of
being informed about the risks and beneﬁts of trans-
plantation, and ability to envision a future beyond
transplantation, using 4-point Likert scales and
5-point scales of agreement. The Medical Outcomes
Study Short Form 36 (SF36) [30,31] and Spitzer
Quality of Life Index (QLI) [32] were also completed.
Once a patient’s pretransplantation survey was re-
ceived, physicians ﬁlled out surveys pretransplantation
indicating their estimates of patient physical health
and estimates for cure and nonrelapse mortality using
identical response options as the patients.
Survivors completed follow-up questionnaires in-
cluding the SF36 and QLI. Bothersome symptoms
were captured using a 5-point Likert scale (“not both-
ered at all,” “bothered a little,” “slightly bothered,”
“moderately bothered,” and “extremely bothered”).
Although depression was not formally assessed, de-
pressive syndrome was considered endorsement of be-
ing “bothered” by depression and 4 or more diagnos-
tic symptoms (anxiety, difﬁculty concentrating, feeling
isolated, fatigue, or memory loss). Individuals with 3
symptoms but who reported being “extremely both-
ered” by depression were likewise considered as hav-
ing depressive syndrome [33]. Follow-up surveys did
not readdress expectations for transplantation out-
comes. Transplant-speciﬁc details were retrieved from
the clinical database.
Statistical Analysis
Univariate comparisons were performed for the
groups classiﬁed as having high expectations or not
using the 2 test, Wilcoxon rank-sum test, or t test as
appropriate. Because of the multiple testing, only P
values .01 are reported as signiﬁcant for these com-
parisons. Scores for the SF36 were calculated accord-
ing to established rules, with the summary scores nor-
malized so that 50 represents the population mean and
a higher scores indicate better functioning [30,31].
Multivariate Cox proportional hazards modeling was
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performed controlling for age, gender, type of trans-
plantation procedure (autologous, related donor, un-
related donor), GVHD prophylaxis (T-cell depletion
or immunosuppressive medications), disease type, and
disease stage. The proportional hazards assumption
was not met for the expectations variable, so models
were constructed breaking the posttransplantation
time course into 2 periods using a maximized partial
likelihood method to ﬁnd the most appropriate break-
point. Interactions between expectations and all po-
tential explanatory variables were examined before
modeling, and no interactions were found. The ﬁnal
multivariate model was built using a forward stepwise
model selection approach with a main effect term for
expectations included in each model. Eleven patients
underwent transplantation from an HLA-mismatched
allogeneic donor and were included in the analysis,
although the small population did not allow for degree
of HLA-matching to be considered as a potential
explanatory variable. Exclusion of HLA-mismatched
patients did not change the conclusions (data not
shown), and they were retained in the analysis.
We then looked for evidence of confounding by
characteristics known or suspected to differ between
patients with high expectations versus others. Thus,
we forced variables reﬂecting patient-reported marital
status and religion, estimates of 1-year treatment-
related mortality, estimates of cure with HSCT, worry
about relapse, and composite scores for physical and
mental functioning from the SF36 into models that
also contained all signiﬁcant covariates.
An adjusted Kaplan-Meier curve comparing the
patients with high expectations versus others was plot-
ted to control for the other clinical prognostic factors
identiﬁed. Type 1 error was set at an alpha of 0.05
but values greater than 0.01 should be interpreted
with caution given the multiple comparisons. All tests




Baseline surveys were sent to 458 patients; 320
were returned, of which 313 (68%) were evaluable.
Responders were more likely to be Caucasian than
nonresponders (95% v 88%; P  .004) and older
(median age 47 years v 44 years; P  .04), but were
otherwise similar in sex, disease stage, and type of
transplantation procedure performed. Two hundred
seventeen (70%) patients strongly agreed with the
positive statement “I am optimistic my transplant will
go well” while 154 (50%) strongly disagreed with the
negative statement “If anything can go wrong with my
transplant, it will” (Spearman correlation 0.41).
Thus, 138 (44%) patients were classiﬁed as having
more optimistic expectations, while 175 (56%) were
considered to have less optimistic expectations. Pa-
tients with higher expectations were more likely to
strongly agree that they felt well informed about the
risks and beneﬁts of transplantation (69% v 50%; P 
.008). Sociodemographic, disease, and treatment char-
acteristics were similar except that patients with
higher expectations were more likely to be married or
living with a partner (Table 1).
Baseline Characteristics
Before transplantation, patients with higher ex-
pectations differed from other patients in self-re-
ported measures of mental and psychologic status, but
not in reported physical functioning. Comparisons
between SF36 and QLI scores are shown in Table 2
for the subset (N  186) who had both baseline and
6-month data available. Before transplantation, pa-
tients with higher expectations had better general
health perceptions (P  .003), mental functioning (P
 .0001), social functioning (P  .01), mental com-
posite scores (P  .004) (all from the SF36), and a
brighter outlook (from the QLI, P  .007) than less-
optimistic patients. Differences were even more sig-
niﬁcant when the entire pretransplantation population
was analyzed (N  320), especially for general health
perceptions (P  .0001), role-emotional functioning
(P  .005), mental composite scores (P  .0004), and
outlook (P  .0008) (data not shown). Self-reported
physical functioning, pain, activity level, and overall
health were not signiﬁcantly different between those
with higher versus lower expectations when the entire
baseline population or the subset surviving to 6
months were analyzed.
Patients who were optimistic about their trans-
plantations going well also reported higher expecta-
tions regarding the likelihood of cure with transplan-
tation (“greater than 90% chance of cure,” 42% v
21%; P  .0009) and recovery by 1 year posttrans-
plantation return to work (38% v 21%; P  .0001),
discontinuation of all transplantation-related medica-
tions (10% v 5%; P  .001), recovery from transplan-
tation (16% v 7%; P .0001), and very good or ex-
cellent health (17% v 9%; P  .0003). They
anticipated a lower likelihood of nonrelapse mortality
(“almost no one dies in ﬁrst year,” 42% v 23%; P 
.001), were less worried about relapse (“not worried at
all,” 27% v 9%; P  .0001), were less worried about
undergoing transplantation (“worry none of the time,”
11% v 3%; P .0001), and were more able to imagine
life beyond the transplantation procedure (66% v
33%; P  .0002) compared with patients who were
less optimistic about their transplantations going well.
Physician estimates of patient health, chance of
cure with transplantation, and treatment-related mor-
tality were not different between patients reporting
high versus lower expectations.
Optimism in HSCT
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Table 1. Patient-, Disease-, and Transplant-Related Characteristics
Variables Optimistic Less Optimistic P Value
N 138 175
Age, median (range) 47 (19–65 yrs) 46 (19–66 yrs) .58
Males 72 (52%) 92 (52%) .94
Marital status .04
Married 117 (85%) 127 (72%)
Single 8 (6%) 27 (15%)
Divorced/separated/widowed 13 (9%) 21 (13%)
Number of children .14
None 18 (13%) 43 (24%)
1–2 78 (56%) 79 (45%)
>3 42 (31%) 53 (31%)
Race .12
White 134 (98%) 162 (93%)
Nonwhite 4 (2%) 13 (7%)
Religion .06
Protestant 50 (36%) 39 (22%)
Roman Catholics 68 (49%) 93 (53%)
Jewish 9 (6%) 12 (7%)
Others/none 11 (9%) 31 (18%)
Strength of religious belief .09
Very religious 32 (23%) 39 (22%)
Somewhat religious 74 (54%) 80 (47%)
Not very religious 24 (18%) 39 (23%)
Not religious at all 7 (5%) 15 (9%)
Education .46
Grade school/some high school 4 (3%) 5 (3%)
High school graduate 31 (22%) 39 (22%)
Some college 32 (23%) 54 (31%)
College graduate 42 (31%) 46 (26%)
Post-graduate 29 (21%) 31 (18%)
Work at diagnosis .57
In school 1 (1%) 4 (2%)
Full time 107 (78%) 140 (80%)
Part time 14 (10%) 17 (10%)
Homemaker 7 (10%) 3 (2%)
Disabled 1 (2%) 2 (1%)
Unemployed 2 (1%) 1 (1%)
Others 5 (4%) 7 (4%)
Disease type .90
AML 15 (11%) 19 (11%)
ALL 6 (4%) 11 (6%)
CML 37 (27%) 44 (25%)
CLL 11 (8%) 12 (7%)
MDS 8 (6%) 12 (7%)
NHL 24 (17%) 40 (22%)
HD 6 (4%) 5 (3%)
MM 29 (21%) 28 (16%)
Other leukemia 1 (1%) 1 (1%)
Others 1 (1%) 3 (2%)
Disease stage .73
Good/early 40 (29%) 55 (31%)
Intermediate 87 (63%) 103 (59%)
Poor/advanced 11 (8%) 17 (10%)
Type of transplant .28
Autologous 55 (40%) 54 (31%)
Related 45 (33%) 68 (39%)
Unrelated 37 (26%) 49 (28%)
Syngeneic 1 (1%) 4 (2%)
Use of TB1 for conditioning 119 (86%) 156 (89%) .43
T cell depletion 26 (19%) 33 (19%) .99
Median follow-up of survivors (range) 28 (12–54 mos) 28 (12–51 mos) .88
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Survival and Nonrelapse Mortality
Figure 1 shows the probability of survival for pa-
tients with and without high expectations adjusted for
disease stage, disease type, type of transplant, patient
age, and occurrence of acute GVHD. Although sur-
vival was better for patients who strongly believed
their transplantations would go well in the ﬁrst 2
months following stem cell infusion, after 2 months
there was no difference and the survival curves over-
lap. Results of multivariate modeling stratiﬁed for
type of transplant are shown in Table 3. As expected,
patients with more advanced disease, older patients,
and those with acute GVHD had worse overall sur-
vival. Controlling for all these variables, patients who
were less certain that their transplantations would go
well also had lower survival limited to the ﬁrst 2
months (84% v 92%; relative risk 2.20, 95% conﬁ-
dence interval [CI] 1.08-4.46; P  .03) and equivalent
Table 2. Quality of Life at Baseline and at Six Months
Baseline At 6 Months
Optimistic Less Optimistic P Value Optimistic Less Optimistic P Value
Short form-36* Median (25th–75th Percentile) Median (25th–75th Percentile)
Physical 80 (60–95) 80 (50–90) .20 65 (50–94) 67 (50–80) .29
Role functioning 75 (0–100) 33 (0–100) .08 50 (0–100) 50 (0–75) .14
Bodily pain 84 (52–100) 74 (52–100) .27 84 (52–100) 74 (52–100) .68
General health 74 (55–87) 62 (45–72) .003 67 (47–77) 60 (47–72) .09
Vitality 55 (40–80) 55 (25–75) .05 50 (30–75) 50 (30–60) .25
Social functioning 100 (62–100) 75 (50–100) .01 88 (62–100) 75 (50–100) .34
Role-emotional 100 (67–100) 100 (33–100) .02 100 (67–100) 100 (67–100) .28
Mental 88 (72–92) 72 (60–84) <.0001 84 (72–92) 80 (68–88) .20
Physical composite 46 (37–56) 44 (34–51) .17 43 (33–51) 40 (31–49) .25
Mental composite 56 (46–59) 52 (41–56) .004 55 (47–59) 54 (45–58) .34
Quality of life index† % Highly Functional % Highly Functional
Activity 62 57 .69 45 36 .35
Daily living 99 95 .16 95 91 .35
Health 65 63 .45 59 53 .50
Support 100 97 .12 99 95 .17
Outlook 89 72 .007 76 72 .59
*Short Form 36: 79 optimistic patients, 103 less optimistic patients with evaluable baseline and six month surveys.
†Quality of Life Index: 82 optimistic patients, 104 less optimistic patients with evaluable baseline and six month surveys.
Figure 1. Overall probability of survival of the optimistic and
less-optimistic groups adjusted for type of transplant, disease stage,
disease type, patient age, and presence of acute GVHD.








Less optimistic (<2 mos
posttransplant) 2.20 (1.08–4.46) .03
Less optimistic (>2 mos
posttransplant) 0.69 (0.41–1.16) .16
Disease stage at transplant .003‡
Good/early 1.00
Intermediate 1.89 (1.03–3.46) .04




NHL/HD 0.63 (0.32–1.21) .16
CML 0.54 (0.30–0.96) .03
CLL 0.35 (0.12–1.07) .06
MM 0.09 (0.01–0.68) .02
Others 0.39 (0.19–0.82) .01
Age at transplant
Age >40 yrs 1.00
Age <40 yrs 0.52 (0.33–0.85) .009
AGVHD
No 1.00
Yes 3.04 (1.84–5.04) <.001
*Model stratiﬁed by type of transplant (autologous v allogeneic);
such that relative risk is the estimate across type of transplant.
†Using the less optimistic group as the baseline category, the
relative risk of mortality for the optimistic group within the ﬁrst 60





survival thereafter (RR 0.69, 95% CI 0.41-1.16; P 
.16). Excluding patients (n  54, 17%) who were the
most optimistic for 1 question and only slightly less
optimistic for the other question (“somewhat agree”
or “somewhat disagree,” as appropriate for the ques-
tion) resulted in similar conclusions. Attempts to di-
vide patients with lower expectations into 2 groups
(eg, neutral or less optimistic for either question [n 
84] v intermediate optimism [n  90]) did not show a
difference in outcome, so these groups were analyzed
together.
A multivariate analysis of nonrelapse mortality
showed similar ﬁndings. Patients with lower expecta-
tions had increased nonrelapse mortality isolated to
the ﬁrst 2 months posttransplantation (relative risk
2.30, 95% CI 1.11-4.77; P  .02) and identical sur-
vival beyond that point adjusting for disease stage,
disease type, patient age, and occurrence of acute
GVHD.
Whether sociodemographics, patient-reported
treatment success rates, or baseline SF-36 physical and
mental functioning affected the relationship between
expectations and outcome was investigated by forcing
potential explanatory variables into the ﬁnal models
with all signiﬁcant covariates. For models that in-
cluded marital status and religion, patient estimates of
treatment-related mortality, patient estimates of
chance of cure with transplantation, worry about re-
lapse, or variables for baseline SF-36 composite phys-
ical or mental functioning showed a persistent associ-
ation of optimistic expectations with survival during
the ﬁrst 2 months after transplantation and equivalent
survival thereafter (Table 4).
Differences among Survivors
Response rates of survivors on the 6-month fol-
low-up surveys were similar between patients with
pretransplantation high expectations versus others
(87% v 90%; P  .4). Table 2 also compares quality-
of-life scores at 6-months. Whereas the 2 patient
groups showed pretransplantation differences in out-
look, general health, and social, role-emotional, and
emotional functioning, these differences were not
present by 6 months posttransplantation. Indeed,
comparison of the 2 groups at 6 months showed no
differences in physical or psychologic functioning as
measured by the SF36 and QLI. Additional analyses
showed no differences in bothersome symptoms (fa-
tigue, anxiety, depression, pain, difﬁculty concentrat-
ing, skin changes, or ﬁnancial problems) or occur-
rence of depressive syndrome.
DISCUSSION
Patients who expressed optimistic expectations
about their transplantation going well did in fact have
a higher survival rate during the ﬁrst 60 days than
those who reported lower expectations. This associa-
tion remained even after statistically controlling for
patients’ physical and mental status. However, by 6
months we were not able to detect a signiﬁcant dif-
ference in survival or quality of life between the groups.






























RR 1.0 1.0 1.0 1.0 1.0 1.0 1.0

















P-value 0.03 0.02 0.02 0.04 0.009 0.05 0.06

















P-value 0.16 0.24 0.23 0.16 0.41 0.09 0.09
*All models include disease stage at transplant, age at transplant, type of disease, and acute GVHD as signiﬁcant prognostic factors.
†Includes covariates for marital status (single or divorced v married) and religion (other religion or catholic v protestant).
‡Includes covariate for patient estimate of 1-year treatment-related mortality (24%, 25–74%, v 75%).
§Includes covariate for patient estimate of cure with transplantation (49%, 50–74%, 75–90% v 90%).
#Includes covariate for patient reported worry about relapse after transplantation (“worry a lot” or “extremely worried” v “worry a little”
v “not worried”).
Includes covariate for pretransplant physical composite score from SF-36 (dichotomized at median) and pretransplant state of health score
from Spitzer Quality of Life Index (dichotomized at median).
¶Includes covariate for pretransplant mental composite score from SF-36 (dichotomized at median).
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Although our assessment of expectations is not
validated, responses were correlated with many other
patient expectations and attitudes, and seemed to re-
ﬂect a globally positive mental attitude. Therefore, it
is tempting to attribute the early survival advantage of
patients with higher expectations to their outlook.
However, it is also possible that higher expectations
are simply a marker for a number of other physical and
behavioral characteristics that account for the ob-
served survival advantage. For example, patients with
optimistic expectations may be slightly healthier,
more compliant, or participate more actively in their
care. These characteristics may initially lead to better
early survival but for some reason not translate into
improved long-term outcomes.
Patients with optimistic expectations also reported
better mental functioning and outlook before trans-
plantation, but they lost this advantage and resembled
patients with lower expectations following the proce-
dure. Several explanations are possible. First, higher
expectations may reﬂect better overall health or dis-
ease status. However, detailed comparisons of the 2
groups of patients before HSCT did not identify any
objective evidence that physical health or disease sta-
tus was different. A second possibility is that the trans-
plantation experience may be so rigorous that even
very enthusiastic patients are unable to maintain their
high level of emotional and mental functioning. Fi-
nally, and most concerning, is the possibility that
higher expectations before transplantation result in a
greater decline in quality of life when difﬁculties do
occur. Our ﬁnding that patients with lower expecta-
tions had relatively stable pretransplantation and
6-month posttransplantation quality of life scores,
while that of the group with higher expectations
started high and fell by 6 months supports this hy-
pothesis.
Our study could not address whether optimistic
expectations for treatment success help patients earlier
in their disease courses or increase the likelihood that
they pursue curative therapy through HSCT. Simi-
larly, we do not know whether other aspects of a
“positive mental attitude” such as determination, in-
volvement in one’s care, and persistent efforts to move
toward recovery improve outcomes, or conversely,
whether depression and hopelessness compromise the
success of therapy. Optimistic expectations may have
beneﬁts to patients that are difﬁcult to quantify or may
affect their transplantation experience regardless of
ultimate survival. We believe these issues deserve fur-
ther study.
The major limitation of this study is that standard-
ized measures of dispositional optimism were not ad-
ministered [29]. Instead, we measured patients’ expec-
tations for the outcome of their transplantation
procedures, a more focussed and speciﬁc measure of
what they were expecting from their treatment. An-
swers to these questions were associated with better
outlook, mental health, role-emotional functioning,
and general health, but not with differences in phys-
ical functioning, role functioning, bodily pain, activity,
health or social support, which are similar to the
ﬁndings of other investigators who measured disposi-
tional optimism using standardized measures [15].
However, given that 44% of our population provided
the most optimistic responses for both questions, our
measure undoubtedly suffers from a ceiling effect that
could limit detection of some differences.
For several reasons, we do not believe that our
observations are limited by the conduct of this study at
a single institution or by self-selection of participants
at baseline and 6 months. First, it is unlikely that
institutional practices could signiﬁcantly inﬂuence any
relationship between expectations and the outcomes
we measured. Second, patients with higher and lower
expectations were well represented in our study and
were equally likely to respond to the 6-month survey.
In summary, a strong belief that the transplanta-
tion procedure will go well is associated with better
survival in the ﬁrst 60 days. While these results derive
from a single institution study and should be con-
ﬁrmed in other populations, it is intriguing to specu-
late on clinical implications. If these self-reported ex-
pectations reﬂect something patients “know” that is
beyond our traditional clinical variables, then optimis-
tic treatment expectations may be considered a good
prognostic sign for early survival. If high expectations
are somehow affecting the medical course of patients,
then a better understanding of the exact mechanism
might lead to interventions that enhance or sustain the
early survival advantage seen in our study. However,
our inability to show an association between pretrans-
plantation expectations and long-term survival or
quality of life also suggests there are limits to what
these attitudes and beliefs can bring about and pro-
vides a cautionary note on the ultimate importance of
entering transplantation with a “positive mental atti-
tude.”
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